Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol (2003) 11.22

Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med (2005) 4.11

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol (2011) 3.71

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41

Mesothelin-family proteins and diagnosis of mesothelioma. Lancet (2003) 2.98

Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol (2012) 2.56

Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med (2012) 2.46

Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer (2008) 1.88

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol (2008) 1.79

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther (2011) 1.76

Epidemiology of peritoneal mesothelioma: a review. Ann Oncol (2006) 1.65

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res (2005) 1.52

Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci (2012) 1.49

Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res (2011) 1.47

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol (2007) 1.46

Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol (2008) 1.46

Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer (2005) 1.39

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol (2012) 1.37

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol (2009) 1.28

Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer (2006) 1.21

New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials. Cancer Manag Res (2015) 1.19

Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res (2008) 1.17

Diffuse malignant peritoneal mesothelioma--an update on treatment. Cancer Treat Rev (2011) 1.14

Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol (2006) 1.12

Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book (2013) 1.06

Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg (2009) 1.06

Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg (2006) 0.99

Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases. Am J Surg Pathol (2004) 0.96

Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol (2006) 0.94

Deciduoid mesothelioma: report of 21 cases with review of the literature. Mod Pathol (2012) 0.93

Malignant peritoneal mesothelioma. World J Gastrointest Surg (2009) 0.92

PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg (2008) 0.89

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res (2016) 0.78

PTEN protein expression in malignant pleural mesothelioma. Tumour Biol (2012) 0.78

Malignant deciduoid mesothelioma: a diagnostic challenge. Arch Pathol Lab Med (2005) 0.78